Neutral
Johnson & Johnson stock (US4781601046): Is its pharma pivot strong enough to drive U.S. investor ret
Johnson & Johnson's strategic shift to innovative medicine and MedTech, following the Kenvue spinoff, aims to strengthen its position in the U.S. heal...
